Sebetralstat KONFIDENT Is the First Phase 3 On-demand HAE Trial to Include Japanese Sites

Honda D, Hide M,2 Ohsawa I, Watanabe Y, Hao J, Smith MD, Yea CM, Audhya PK, Riedl MA, Cohn DM
Japanese Dermatological Association

Sebetralstat as Oral On-demand Treatment for Hereditary Angioedema: Interim Analysis of Demographics and Attack Characteristics from the Open-label KONFIDENT-S

Henriette Farkas, Marc A. Riedl, Emel Aygören-Pürsün, William R. Lumry, Andrea Zanichelli, James Hao, Matthew Iverson, Michael D. Smith, Christopher M. Yea, Paul K. Audhya, Jonathan A. Bernstein, Marcus Maurer, Danny M. Cohn
EAACI 2024

Hereditary Angioedema (HAE) Patients Answer: Why Do Attacks Go Untreated?

Radojicic C, Busse P, O’Connor M, Danese S, Ulloa J, Desai V, Andriotti T, Audhya PK, Christiansen S
EAACI 2024

Attack Characteristics in Patients with Hereditary Angioedema Receiving Non-Androgen Long-term Prophylaxis

Lumry W, Baptist A, Soteres D, Manning M, Earl L, Connolly H, Audhya PK, Wang A, Andriotti T, Desai V
EAACI 2024

Treatment of HAE Attacks with Anticipated Future Oral On-Demand Therapies as Reported by Patients

Valerieva A, Jones D, van Kooten S, Malloy N, Heckmann M, Betschel S
EAACI 2024

Patient-Reported Benefits of Early On-Demand Treatment of HAE Attacks

Longhurst H, Guilarte M, van Kooten S, Malloy N, Heckmann M, Busse P
EAACI 2024

A sensitive and specific assay to characterize plasma kallikrein activity in plasma from hereditary angioedema patients

Lee D, Ghannam A, Murugesan N, Vincent D, Mogg A, Smith M, Hampton S, Feener E
EAACI 2024

Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers

Savic S, El-Shanawany T, Gurugama P, Jain R, Danese S, Ulloa J, Desai V, Audhya P, Yong P
EAACI 2024

Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks

Yong P, El-Shanawany T, Gurugama P, Jain R, Danese S, Ulloa J, Desai V, Audhya P, Savic S
EAACI 2024

Unmet Needs Associated with Non-androgen Injectable Long-term Prophylaxis (LTP) Therapies for HAE

Lumry W, Baptist A, Soteres D, Manning M, Wynne-Cattanach K, Birija L, Audhya PK, Wang A, Andriotti T, Desai V
EAACI 2024

Sebetralstat KONFIDENT Is the First Phase 3 On-demand HAE Trial to Include Japanese Sites

Sebetralstat as Oral On-demand Treatment for Hereditary Angioedema: Interim Analysis of Demographics and Attack Characteristics from the Open-label KONFIDENT-S

Hereditary Angioedema (HAE) Patients Answer: Why Do Attacks Go Untreated?

Attack Characteristics in Patients with Hereditary Angioedema Receiving Non-Androgen Long-term Prophylaxis

Treatment of HAE Attacks with Anticipated Future Oral On-Demand Therapies as Reported by Patients

Patient-Reported Benefits of Early On-Demand Treatment of HAE Attacks

A sensitive and specific assay to characterize plasma kallikrein activity in plasma from hereditary angioedema patients

Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers

Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks

Unmet Needs Associated with Non-androgen Injectable Long-term Prophylaxis (LTP) Therapies for HAE

About

Science

Pipeline

Careers

Contact